<a href="https://laohu8.com/S/IBIO">iBio Inc.</a> Announces Proposed Public Offering to Advance Preclinical Programs
iBio, Inc. (Nasdaq: IBIO), an innovator in precision antibody therapies, has announced the commencement of an underwritten public offering. This offering includes pre-funded warrants to purchase shares of the company's common stock, as well as accompanying Series G and Series H warrants. All securities in this offering will be sold by iBio. The proceeds from the offering are intended to advance iBio's preclinical cardiometabolic programs, including the IBIO-610 and IBIO-600 programs, through key development milestones, and to support other preclinical pipeline assets. Any remaining funds will be used for working capital and general corporate purposes. Leerink Partners is leading the offering as the bookrunning manager, with LifeSci Capital and Oppenheimer & Co. also serving as bookrunning managers. Brookline Capital Markets is acting as a financial advisor to iBio.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iBio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-081419), on August 21, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.